Streetwise Reports' Article Archives — June 2015 back to current month (4)
Biotech investors are abuzz over immune checkpoint inhibitors and T-cell therapies, but which ones do you pick? JonesTrading Institutional Services Senior Equity Analyst George Zavoico is moving rapidly to initiate coverage on some key names in this space, and is casting a wide net in hopes of catching winners. In this interview with The Life Sciences Report, Zavoico delineates some movers and shakers in the cancer immunotherapy field, and recommends investors keep their pencils sharp and eyes open as data emerge over the next year or two.
The list of problems with investing in micro-cap biotech stocks begins with extreme volatility and lack of liquidity and ends with the inability to get validation from sophisticated investors who are unable to own such small companies. Nevertheless, sift through the pile and investors can find gems. Joseph Pantginis of ROTH Capital Partners recognizes the characteristics that make some of these tiny companies move up the ladder in market valuation. In this interview with The Life Sciences Report, Pantginis discusses five names with development programs capable of generating dramatic growth.
Analyst Pooya Hemami of Edison Investment Research casts a wide net when it comes to investment opportunities in the life sciences. You name it, his universe includes it: artificial sweeteners, blood tests, sleep aids, cancer treatments, brain health. In this interview with The Life Sciences Report, Dr. Hemami reflects on the biotech market at midyear, and describes a robust basket of outstanding companies with pipeline treasures.
Chen Lin produces a monthly scorecard that tracks the performance of the stocks in which he invests. Every month, he reveals how he is doing in his newsletter, What Is Chen Buying? What is Chen Selling? In this interview with The Life Sciences Report, Lin identifies undervalued companies with paradigm-shattering pipeline products that could turn small change into big profits.
|"DRRX's psoriasis trial is on target for topline data by year-end 2019."|